Pharmaceutical Executive-05-01-2010

Features
Pharmaceutical Executive

May 25, 2010

One year after the rash of pharma megamergers, Pharm Exec's annual listing of the industry's top-selling companies looks a little different. Find out who disappeared from the list, and what up-and-coming companies finally broke into the top 50.

Issue PDF
Pharmaceutical Executive

May 01, 2010

One Pill Makes You Better?

Pharmaceutical Executive

Timely and accessible information can help break through the firewall of regulation.

Pharmaceutical Executive
Features

May 01, 2010

The Orphan Drug Act of 1983 has been a roaring success. So why is everybody trying to mess with it?

Pharmaceutical Executive
Features

May 01, 2010

The new world of mobile applications is sparking creative platforms for reaching consumers and physicians.

Pharmaceutical Executive
Features

May 01, 2010

How will US healthcare reform affect drug pricing, revenue, and compliance?

Pharmaceutical Executive
From the Editor

May 01, 2010

Cash-rich Big Pharmas are hedging their bets to cover both segments under the rubric of "diversification." If it sticks to the wall, then buy it.

Pharmaceutical Executive

The three-way race for control of Parliament leaves the future of the British pharmaceutical industry in the balance.

Pharmaceutical Executive
Features

May 01, 2010

A panel of bankers and industry executives discuss what's ahead in deals for 2010.

Pharmaceutical Executive

Marketers must focus on getting busy women the help they need in making critical decisions about their healthcare.

Pharmaceutical Executive
Washington Report

May 01, 2010

Under the new healthcare regime, pharma will ante up fees and rebates in return for expanded sales and safeguards.